MedPath

A study to determine whether introducing a Valsalva assist device into normal ambulance service care can reduce the number of patients with supraventricular tachycardia who need to be taken to hospital.

Phase 3
Completed
Conditions
Emergency treatment of supraventricular tachycardia (SVT)
Circulatory System
Registration Number
ISRCTN16145266
Lead Sponsor
South Western Ambulance Service NHS Foundation Trust
Brief Summary

2023 Protocol article in https://doi.org/10.1136/bmjopen-2023-073315 (added 09/06/2023)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
865
Inclusion Criteria

1. Adult patients (above 17 years)
2. Record of a Valsalva manoeuvre for presumed supraventricular tachycardia having been delivered by an ambulance clinician asigned to an ambulance station cluster.

Exclusion Criteria

1. Subsequent withdrawal of patient consent to use data
2. Data from participants who are prisoners at the time of treatment
3. Patients with permanent lack of capacity as recorded by the treating clinician
4. Patients solely treated by a SWASFT resource not from one of the included ambulance station clusters e.g. Air Ambulance, Hazardous Area Response Team, Tiverton Minor Injuries Unit, British Association for Immediate Care (BASICS) Doctor
5. Data from patients previously included in the study will be excluded from the primary analysis but will be used in other secondary analyses
6. Patients who have previously registered with the National Data Opt-out service

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Conveyance of patient to hospital as recorded in the Electronic Patient Care Record (ePCR)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath